JPMorgan Chase & Co. Buys 528,753 Shares of IQVIA Holdings Inc. $IQV

JPMorgan Chase & Co. boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 16.2% in the fourth quarter, HoldingsChannel reports. The firm owned 3,799,600 shares of the medical research company’s stock after acquiring an additional 528,753 shares during the period. JPMorgan Chase & Co.’s holdings in IQVIA were worth $856,468,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in IQVIA by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after purchasing an additional 159,899 shares during the last quarter. Geode Capital Management LLC increased its holdings in IQVIA by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after purchasing an additional 24,453 shares during the last quarter. Alliancebernstein L.P. increased its holdings in IQVIA by 1.2% in the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after purchasing an additional 41,643 shares during the last quarter. Boston Partners bought a new stake in IQVIA in the third quarter valued at about $676,698,000. Finally, Artisan Partners Limited Partnership increased its holdings in IQVIA by 4.9% in the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after purchasing an additional 161,085 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.4%

IQV stock opened at $186.27 on Wednesday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a market capitalization of $31.09 billion, a P/E ratio of 23.08, a P/E/G ratio of 1.58 and a beta of 1.21. The business has a 50-day moving average of $172.86 and a 200-day moving average of $194.33. IQVIA Holdings Inc. has a fifty-two week low of $153.01 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its board has initiated a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Morgan Stanley set a $225.00 price target on IQVIA in a report on Thursday, May 7th. HSBC set a $210.00 price target on IQVIA in a report on Wednesday, June 3rd. Truist Financial lowered their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Finally, Weiss Ratings downgraded IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $224.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.